The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial

Michael Tvilling Madsen; Jawad Ahmad Zahid; Christine Hangaard Hansen; Ole Grummedal; Jessica Roberts Hansen; Anders Isbrand; Ulla Overgaard Andersen; Lars Juel Andersen; Mustafa Taskiran; Erik Simonsen; Ismail Gögenur

doi:10.1016/j.jpsychires.2019.09.014

The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial

Michael Tvilling Madsen^*, Jawad Ahmad Zahid, Christine Hangaard Hansen, Ole Grummedal, Jessica Roberts Hansen, Anders Isbrand, Ulla Overgaard Andersen, Lars Juel Andersen, Mustafa Taskiran, Erik Simonsen, Ismail Gögenur

^*Corresponding author af dette arbejde

2 Citationer (Scopus)

Abstract

Background: Depression following acute coronary syndrome is prevalent and associated with increased mortality and morbidity. Melatonin may function as a primary prophylactic antidepressant substance and alleviate depressive symptoms. The study was undertaken to determine if melatonin administered following an acute coronary syndrome (ACS) could prevent development of depression. Methods: The study was a double-blinded, placebo-controlled, multicenter, randomized clinical trial performed in five primary care cardiology departments at Zealand, Denmark. Included patients were adults patients, free of depression at baseline, included at the latest 4 weeks after acute coronary syndrome. Twenty-five mg melatonin or placebo was administered 1 h before participants’ bedtime for 12 weeks. The primary outcome is Major Depression Inventory (MDI) measured every two weeks throughout the trial. Incidence of depression was apriori defined as MDI score ≥ 21 during the trial. Reported exploratory outcomes were patterns of dropout and safety outcomes. Results: 1220 patients were screened and 252 participants were randomized in a 1:1 ratio. Baseline MDI score in the melatonin and placebo group were, respectively, 6.18 (CI 5.32–7.05) and 5.98 (CI 5.19–6.77). No significant intergroup differences were found during the study in the intention-to-treat analysis or per-protocol analysis. Cumulative events of depressive episodes during the 12 weeks were six in the melatonin group and four in the placebo group. A significant drop in depressive symptoms were present throughout the study period. No intergroup differences were present in dropouts or adverse events. Conclusions: Melatonin showed no prophylactic antidepressant effect following acute coronary syndrome. The non-significant results might be due to a type II error or melatonin might not be able to prevent development of depressive symptoms following ACS.

Originalsprog	Engelsk
Tidsskrift	Journal of Psychiatric Research
Vol/bind	119
Sider (fra-til)	84-94
Antal sider	11
ISSN	0022-3956
DOI	https://doi.org/10.1016/j.jpsychires.2019.09.014
Status	Udgivet - dec. 2019

Adgang til dokumentet

10.1016/j.jpsychires.2019.09.014

Andre filer og links

Link to publication in Scopus

Citationsformater

Madsen, M. T., Zahid, J. A., Hansen, C. H., Grummedal, O., Hansen, J. R., Isbrand, A., Andersen, U. O., Andersen, L. J., Taskiran, M., Simonsen, E., & Gögenur, I. (2019). The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial. Journal of Psychiatric Research, 119, 84-94. https://doi.org/10.1016/j.jpsychires.2019.09.014

The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial. / Madsen, Michael Tvilling; Zahid, Jawad Ahmad; Hansen, Christine Hangaard et al.
I: Journal of Psychiatric Research, Bind 119, 12.2019, s. 84-94.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Madsen, MT, Zahid, JA, Hansen, CH, Grummedal, O, Hansen, JR, Isbrand, A, Andersen, UO, Andersen, LJ, Taskiran, M , Simonsen, E & Gögenur, I 2019, 'The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial', Journal of Psychiatric Research, bind 119, s. 84-94. https://doi.org/10.1016/j.jpsychires.2019.09.014

@article{e983ea0b76ea48b78d9a7d88c102893e,

title = "The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial",

abstract = "Background: Depression following acute coronary syndrome is prevalent and associated with increased mortality and morbidity. Melatonin may function as a primary prophylactic antidepressant substance and alleviate depressive symptoms. The study was undertaken to determine if melatonin administered following an acute coronary syndrome (ACS) could prevent development of depression. Methods: The study was a double-blinded, placebo-controlled, multicenter, randomized clinical trial performed in five primary care cardiology departments at Zealand, Denmark. Included patients were adults patients, free of depression at baseline, included at the latest 4 weeks after acute coronary syndrome. Twenty-five mg melatonin or placebo was administered 1 h before participants{\textquoteright} bedtime for 12 weeks. The primary outcome is Major Depression Inventory (MDI) measured every two weeks throughout the trial. Incidence of depression was apriori defined as MDI score ≥ 21 during the trial. Reported exploratory outcomes were patterns of dropout and safety outcomes. Results: 1220 patients were screened and 252 participants were randomized in a 1:1 ratio. Baseline MDI score in the melatonin and placebo group were, respectively, 6.18 (CI 5.32–7.05) and 5.98 (CI 5.19–6.77). No significant intergroup differences were found during the study in the intention-to-treat analysis or per-protocol analysis. Cumulative events of depressive episodes during the 12 weeks were six in the melatonin group and four in the placebo group. A significant drop in depressive symptoms were present throughout the study period. No intergroup differences were present in dropouts or adverse events. Conclusions: Melatonin showed no prophylactic antidepressant effect following acute coronary syndrome. The non-significant results might be due to a type II error or melatonin might not be able to prevent development of depressive symptoms following ACS.",

keywords = "Acute coronary syndrome, Depression, Melatonin, Placebo, Primary prophylactic, Randomized controlled trial",

author = "Madsen, {Michael Tvilling} and Zahid, {Jawad Ahmad} and Hansen, {Christine Hangaard} and Ole Grummedal and Hansen, {Jessica Roberts} and Anders Isbrand and Andersen, {Ulla Overgaard} and Andersen, {Lars Juel} and Mustafa Taskiran and Erik Simonsen and Ismail G{\"o}genur",

year = "2019",

month = dec,

doi = "10.1016/j.jpsychires.2019.09.014",

language = "English",

volume = "119",

pages = "84--94",

journal = "Journal of Psychiatric Research",

issn = "0022-3956",

publisher = "Pergamon Press",

}

TY - JOUR

T1 - The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome

T2 - The MEDACIS randomized clinical trial

AU - Madsen, Michael Tvilling

AU - Zahid, Jawad Ahmad

AU - Hansen, Christine Hangaard

AU - Grummedal, Ole

AU - Hansen, Jessica Roberts

AU - Isbrand, Anders

AU - Andersen, Ulla Overgaard

AU - Andersen, Lars Juel

AU - Taskiran, Mustafa

AU - Simonsen, Erik

AU - Gögenur, Ismail

PY - 2019/12

Y1 - 2019/12

N2 - Background: Depression following acute coronary syndrome is prevalent and associated with increased mortality and morbidity. Melatonin may function as a primary prophylactic antidepressant substance and alleviate depressive symptoms. The study was undertaken to determine if melatonin administered following an acute coronary syndrome (ACS) could prevent development of depression. Methods: The study was a double-blinded, placebo-controlled, multicenter, randomized clinical trial performed in five primary care cardiology departments at Zealand, Denmark. Included patients were adults patients, free of depression at baseline, included at the latest 4 weeks after acute coronary syndrome. Twenty-five mg melatonin or placebo was administered 1 h before participants’ bedtime for 12 weeks. The primary outcome is Major Depression Inventory (MDI) measured every two weeks throughout the trial. Incidence of depression was apriori defined as MDI score ≥ 21 during the trial. Reported exploratory outcomes were patterns of dropout and safety outcomes. Results: 1220 patients were screened and 252 participants were randomized in a 1:1 ratio. Baseline MDI score in the melatonin and placebo group were, respectively, 6.18 (CI 5.32–7.05) and 5.98 (CI 5.19–6.77). No significant intergroup differences were found during the study in the intention-to-treat analysis or per-protocol analysis. Cumulative events of depressive episodes during the 12 weeks were six in the melatonin group and four in the placebo group. A significant drop in depressive symptoms were present throughout the study period. No intergroup differences were present in dropouts or adverse events. Conclusions: Melatonin showed no prophylactic antidepressant effect following acute coronary syndrome. The non-significant results might be due to a type II error or melatonin might not be able to prevent development of depressive symptoms following ACS.

AB - Background: Depression following acute coronary syndrome is prevalent and associated with increased mortality and morbidity. Melatonin may function as a primary prophylactic antidepressant substance and alleviate depressive symptoms. The study was undertaken to determine if melatonin administered following an acute coronary syndrome (ACS) could prevent development of depression. Methods: The study was a double-blinded, placebo-controlled, multicenter, randomized clinical trial performed in five primary care cardiology departments at Zealand, Denmark. Included patients were adults patients, free of depression at baseline, included at the latest 4 weeks after acute coronary syndrome. Twenty-five mg melatonin or placebo was administered 1 h before participants’ bedtime for 12 weeks. The primary outcome is Major Depression Inventory (MDI) measured every two weeks throughout the trial. Incidence of depression was apriori defined as MDI score ≥ 21 during the trial. Reported exploratory outcomes were patterns of dropout and safety outcomes. Results: 1220 patients were screened and 252 participants were randomized in a 1:1 ratio. Baseline MDI score in the melatonin and placebo group were, respectively, 6.18 (CI 5.32–7.05) and 5.98 (CI 5.19–6.77). No significant intergroup differences were found during the study in the intention-to-treat analysis or per-protocol analysis. Cumulative events of depressive episodes during the 12 weeks were six in the melatonin group and four in the placebo group. A significant drop in depressive symptoms were present throughout the study period. No intergroup differences were present in dropouts or adverse events. Conclusions: Melatonin showed no prophylactic antidepressant effect following acute coronary syndrome. The non-significant results might be due to a type II error or melatonin might not be able to prevent development of depressive symptoms following ACS.

KW - Acute coronary syndrome

KW - Depression

KW - Melatonin

KW - Placebo

KW - Primary prophylactic

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85072777364&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2019.09.014

DO - 10.1016/j.jpsychires.2019.09.014

M3 - Journal article

C2 - 31586772

AN - SCOPUS:85072777364

SN - 0022-3956

VL - 119

SP - 84

EP - 94

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

ER -

The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater